SLC1A2 and astrocytoma (excluding glioblastoma): Batarseh et al. (2017) revealed that Aβo induced astrocyte inflammatory activation and decreased the expression of glutamate transporter-1 (GLT1), glucose transporter-1 (GLUT1), postsynaptic density protein 95 (PSD-95; a postsynaptic marker) and synaptosomal-associated protein 25 (SNAP-25, a presynaptic marker) in human astrocytoma CCF-STTG1 cells and neuroblastoma SH-SY5Y cells transfected with amyloid precursor protein (APP) (SH-SY5Y-APP cells) [109].